ONCASPAR (E. coli asparaginase), antineoplastic agent

HAEMATOLOGY - New medicinal product
Opinions on drugs - Posted on Oct 13 2016

Reason for request

Inclusion

No clinical benefit demonstrated by comparison with KIDROLASE in the management of newly diagnosed or relapsed acute lymphoblastic leukaemia in patients without hypersensitivity to native E. coli asparaginase.

  

  • ONCASPAR has Marketing Authorisation in combination with other antineoplastic agents for the treatment of acute lymphoblastic leukaemia in children and adults.
  • It is a first-line treatment of newly diagnosed or relapsed acute lymphoblastic leukaemia in patients without hypersensitivity (clinical allergy or silent inactivation) to native E. coli asparaginase (KIDROLASE).

 

 


Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Therapeutic use

-

Contact Us

Évaluation des médicaments